The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 25, 2020
Filed:
Mar. 23, 2016
Applicant:
Algipharma As, Sandvika, NO;
Inventors:
Assignee:
AlgiPharma AS, Sandvika, NO;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/734 (2006.01); A61K 31/443 (2006.01); A61K 31/4245 (2006.01); A61K 31/47 (2006.01); A61K 45/06 (2006.01); A61K 31/4164 (2006.01); A61K 31/405 (2006.01); A61K 31/496 (2006.01); A61K 31/4965 (2006.01); A61K 31/43 (2006.01); A61K 31/7036 (2006.01);
U.S. Cl.
CPC ...
A61K 31/734 (2013.01); A61K 31/405 (2013.01); A61K 31/4164 (2013.01); A61K 31/4245 (2013.01); A61K 31/43 (2013.01); A61K 31/443 (2013.01); A61K 31/47 (2013.01); A61K 31/496 (2013.01); A61K 31/4965 (2013.01); A61K 31/7036 (2013.01); A61K 45/06 (2013.01);
Abstract
A method is for the treatment of a condition in a subject, which arises from or is associated with CFTR dysfunction. The method includes administering to the subject an effective amount of a CFTR modulator together with an effective amount of an alginate oligomer. The condition can be cystic fibrosis (CF), non-compound CFTR gene mutation heterozygosity, abnormal mucus clearance in the respiratory tract and/or breathing difficulties resulting from chronic particulate inhalation, COPD, chronic bronchitis, emphysema, bronchiectasis, asthma or chronic sinusitis, or a complication of any of these.